Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characteristics of patients with EGFR-mutant non-small-cell lung cancer who benefited from immune checkpoint inhibitors.
Ichihara E, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ichihara E, et al. Among authors: kishino d. Cancer Immunol Immunother. 2021 Jan;70(1):101-106. doi: 10.1007/s00262-020-02662-0. Epub 2020 Jul 10. Cancer Immunol Immunother. 2021. PMID: 32648165 Free PMC article.
Significance of PD-L1 expression in the cytological samples of non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Hara N, Ichihara E, Harada D, Inoue K, Fujiwara K, Hosokawa S, Kishino D, Haruyuki K, Ochi N, Oda N, Hotta K, Maeda Y, Kiura K. Hara N, et al. Among authors: kishino d. J Cancer Res Clin Oncol. 2021 Dec;147(12):3749-3755. doi: 10.1007/s00432-021-03615-5. Epub 2021 Mar 29. J Cancer Res Clin Oncol. 2021. PMID: 33779840
Erratum to: Impact of previous thoracic radiation therapy on the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer.
Hosokawa S, Ichihara E, Bessho A, Harada D, Inoue K, Shibayama T, Kishino D, Harita S, Ochi N, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Hosokawa S, et al. Among authors: kishino d. Jpn J Clin Oncol. 2021 Aug 1;51(8):1348. doi: 10.1093/jjco/hyab113. Jpn J Clin Oncol. 2021. PMID: 34215885 No abstract available.
Response to letter re: The effects of antibiotics on the efficacy of immune-checkpoint inhibitors in non-small cell lung cancer patients differ according to PD-L1 expression.
Ochi N, Ichihara E, Takigawa N, Harada D, Inoue K, Shibayama T, Hosokawa S, Kishino D, Harita S, Oda N, Hara N, Hotta K, Maeda Y, Kiura K. Ochi N, et al. Among authors: kishino d. Eur J Cancer. 2021 Nov;157:523-524. doi: 10.1016/j.ejca.2021.07.044. Epub 2021 Sep 1. Eur J Cancer. 2021. PMID: 34479780 No abstract available.
More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance.
Ando C, Ichihara E, Yokoyama T, Inoue K, Tamura T, Fujiwara K, Oda N, Kano H, Kishino D, Watanabe K, Inoue M, Ochi N, Onishi F, Ichikawa H, Kobe H, Tachibana S, Hotta K, Maeda Y, Kiura K. Ando C, et al. Among authors: kishino d. J Cancer Res Clin Oncol. 2023 Jul;149(8):4933-4938. doi: 10.1007/s00432-022-04415-1. Epub 2022 Oct 29. J Cancer Res Clin Oncol. 2023. PMID: 36308525
42 results